Biotechnology and Biosimilars in Emerging Countries
In the pipeline, the number of bio-betters is around 450, and the number of biosimilars being developed is nearly 650. Most biosimilars and bio-betters are developed by such companies as Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer, and Sanofi as well as large generic pharmaceutical companies such as US Mylan, Swiss Sandoz, and Israel TEVA. But the pipeline includes close to 200 biopharmaceuticals being developed or already produced in emerging and developing countries[1]. These include China, and India, but also Argentina Brazil, Korea, and Russia. The entry of these companies based in emerging countries in the production of biosimilars comes from different ways. There are alliances such as those between US Mylan and India’s Biocon announced in 2013 to commercialize Biocon’s recombinant insulin, or between LG Life Sciences (Korea) and Mochida (Japan) for the development of a biosimilar adalimumab. There are also partnerships in countries such as Brazil, where Merck KGaA’s biological division, Merck Serono, is signing agreements with Bionovis. Other companies such as Biocad in Russia, or Amega, Biosidus, and Insud in Argentina are developing and marketing biosimilars on their own.
- Biosimilars as learning ground for health biotechnology in emerging countries
- From imitation to innovation in the pharmaceutical industry
- Regulatory environments and learning in emerging country biopharmaceuticals
- Different avenues for catching up in the biopharmaceutical industry: collaborate, imitate, or import
|
Manuscript Due
|
September 11, 2015
|
|
First Round of Reviews
|
December 04, 2015
|
|
Publication Date
|
January 29, 2016
|
Lead Guest Editor:
Guest Editors: